KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Accounts Payables: 2009-2025

Historic Accounts Payables for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $21.7 million.

  • Acadia Pharmaceuticals' Accounts Payables rose 13.97% to $21.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.7 million, marking a year-over-year increase of 13.97%. This contributed to the annual value of $16.2 million for FY2024, which is 7.70% down from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Accounts Payables is $21.7 million, which was up 8.21% from $20.1 million recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Accounts Payables peaked at $21.7 million during Q3 2025, and registered a low of $6.9 million during Q4 2021.
  • In the last 3 years, Acadia Pharmaceuticals' Accounts Payables had a median value of $18.8 million in 2023 and averaged $18.2 million.
  • Within the past 5 years, the most significant YoY rise in Acadia Pharmaceuticals' Accounts Payables was 122.47% (2021), while the steepest drop was 19.04% (2021).
  • Over the past 5 years, Acadia Pharmaceuticals' Accounts Payables (Quarterly) stood at $6.9 million in 2021, then soared by 85.37% to $12.7 million in 2022, then spiked by 37.64% to $17.5 million in 2023, then fell by 7.70% to $16.2 million in 2024, then increased by 13.97% to $21.7 million in 2025.
  • Its last three reported values are $21.7 million in Q3 2025, $20.1 million for Q2 2025, and $18.1 million during Q1 2025.